QRS Diagnostic, the company behind Universal ECGTM and OrbitTM spirometer, are set to revolutionize the cardiology field with ground breaking advancement in the ECG space. Using an advanced algorithm the new ECG from QRS provides instant feedback via a Cardiac Electrical Biomarker (CEB) for the real time detection of ECG changes suggestive of an AMI. This is in addition to being able to derive a 15 lead ECG from just 5 electrodes.
The VectraplexECG by QRS provides a simple and immediate colour coded response (CEB), indicating the likelihood of an AMI. This CEB has been proven to be an accurate predictor of Troponin levels in the patient’s blood which has been the gold standard of AMI detection. The CEB is a non-invasive and cost-effective complement to a troponin draw allowing the ECG to provide ongoing feedback of the heart’s health.
Placing only 5 electrodes for a 15 lead ECG is in itself a ground-breaking advancement; reducing time, placement error, and the cost of consumables. No further training is required as the 5 leads are a subset of the standard 12 lead placement: the 4 limb leads as well as V2.
Medilogic will be supplying the VectroplexECG product to distributors early 2018. We will be organising training and marketing assistance leading up to the product launch. This is an extremely exciting development in the ECG space and we are expecting the VectraplexECGs to be the number one choice for medical professionals in the world.